{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:16:21Z","timestamp":1790954181173,"version":"4.1.0"},"reference-count":0,"publisher":"MRE Press","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: Trigeminal neuralgia (TN) is a severe neuropathic pain condition in the orofacial region, with carbamazepine recommended as the first-line treatment. Nonetheless, its application is constrained by unfavorable drug responses and side effects. The objective of this research was to assess the effectiveness and safety of lacosamide, a third-generation anticonvulsant, in individuals with TN, and to juxtapose the findings with observational records from recently diagnosed TN patients who underwent carbamazepine monotherapy within the corresponding timeframe. Methods: An 8-week flexible dose titration of lacosamide was performed on newly diagnosed 12 TN patients who were divided into two groups: 200 mg\/day (n = 5), and 400 mg\/day (n = 7). Outcome measures included average pain score, Brief Pain Inventory-facial scores, and side effects. Patients were followed-up at 2, 4 and 8 weeks after baseline. Results: The percentage change of pain score at 4-week visit was compared between both lacosamide groups and patients receiving carbamazepine (n = 6) for four weeks during concurrent period. Both lacosamide groups experienced a decrease in pain score at 2-week follow-up, and differences in average pain score reduction were not observed between the two groups across all visits (p &gt; 0.05). The mean Brief Pain Inventory-facial score in the lacosamide 200 mg\/day group was higher than that in the 400 mg\/day group at the 2-week follow-up (p = 0.03). Interestingly, the 4-week follow-up revealed that there were no significant variances in pain intensity between the lacosamide and the contemporaneous carbamazepine cohorts (p &gt; 0.05). Frequently noted adverse events were mild somnolence (n = 9), slight vertigo (n = 5), and emotional lability (n = 2) without instances of severe adverse drug responses. Conclusions: Lacosamide demonstrates potential as a therapeutic option for patients suffering from trigeminal neuralgia. Clinical Trial Registration: TCTR20210811002.<\/jats:p>","DOI":"10.22514\/jofph.2025.011","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:27:12Z","timestamp":1741771632000},"source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of lacosamide in patients with trigeminal neuralgia: an 8-week pilot dose-escalation study"],"prefix":"10.22514","member":"26027","published-online":{"date-parts":[[2025]]},"container-title":["Journal of Oral &amp; Facial Pain and Headache"],"original-title":[],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:27:12Z","timestamp":1741771632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jofph.com\/articles\/10.22514\/jofph.2025.011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":0,"URL":"https:\/\/doi.org\/10.22514\/jofph.2025.011","relation":{},"ISSN":["2333-0376","2333-0384"],"issn-type":[{"value":"2333-0376","type":"electronic"},{"value":"2333-0384","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}